AstraZeneca's in-development lung cancer pill extended progression-free survival by more than a year in new Phase II data, a positive sign for a drug the company believes can bring in $3 billion in annual sales at its peak.
California has become the latest government to set up a precision medicine initiative. And like President Barack Obama's nationwide plan, the success of the state initiative will rest in part on whether it can combine and make sense of different sources of data.
Point-of-care diagnostics are picking up steam in the industry, with companies rolling out mobile platforms and smartphone apps that can quickly identify diseases. VisualDx is taking a different approach, offering a quick diagnostic tool that uses images rather than text to help physicians screen for certain conditions.
Apple just gained a powerful ally in its push to make ResearchKit a core component of the health research toolkit. The Silicon Valley tech giant has tapped IBM for access to Watson, the data-mining and predictive analytics capabilities of which will be applied to health research.
A survey by analysts at William Blair has found that biopharma R&D staffers think making better use of existing data is their best hope of improving productivity. Almost half of the 133 respondents said the topic was the biggest remaining opportunity to improve R&D.
PatientsLikeMe has struck a 5-year deal to support R&D at AstraZeneca. The agreement tops off a busy and important 12 months for the patient network, in which it has also expanded relationships with Biogen, Roche's Genentech and Swiss biopharma Actelion.
PatientsLikeMe and Biogen revealed promising results from a new study that shows wearable devices can help monitor individuals with MS over time, providing additional information to clinicians and potentially increasing adherence among patients.
Quintiles is further entrenching itself in Latin America, striking a deep-rooted alliance with a research site in Buenos Aires to widen its global network of trusted partners.
Swedish contract drug developer Recipharm has signed a deal with Virginia's Synthonics, investing in the biotech and lending its expertise in the development of new compounds.
Iris Pharma and Oculos Clinical Research, two CROs focused on the eye, have inked a strategic alliance to boost their profiles in the contracting world.